Drug intelligence / Profile preview

fangbianfang

Development stage: Preclinical
Lead developer: The First Affiliated Hospital
Administration: Oral

Overview

Fangbianfang is a Traditional Chinese Medicine (TCM) formula, specifically identified in clinical trials as "Xiao Chai Hu Tang He Wu Zi Ding Chuan Wen Fei Hua Tan Tang". It is being investigated for its clinical efficacy in the tripartite sequential treatment of novel coronavirus infection in elderly patients, administered orally in combination with standardized Western medicine.

Other names: Xiao Chai Hu Tang He Wu Zi Ding Chuan Wen Fei Hua Tan Tang防变方“小柴胡汤合五子定喘温肺化痰汤”

Beyond the preview

Go deeper on fangbianfang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fangbianfang.

Explore the full profile